Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's Innovent Biologics Raises $100 Million in C Round

publication date: Jan 22, 2015
Innovent Biologics of Suzhou announced a very significant $100 million C round funding, which the company will use to advance its portfolio of eight biologic drug candidates. Founded in 2011, Innovent already has filed four IND applications in China. The company's portfolio consists of a combination of innovative candidates and biosimilars. In addition, Innovent also offers biologic CMO services to other companies from its large EMEA/FDA/cGMP compliant facility in Suzhou's BioBay Park. Innovent's goal is to provide high quality biologic drugs to China at a reasonable price, with products in the oncology, diabetes and autoimmune sectors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital